<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytotoxic function of CD4+ Th1 cells is mediated by Fas (CD95, <z:chebi fb="16" ids="53704">APO</z:chebi>-1) and its ligand (Fas ligand) </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies using nontransformed B cells and the Ramos Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) B-cell line cells show that CD40 ligation at the B-cell surface by activated, CD40 ligand (CD40L)-bearing, CD4+ T cells upregulates Fas expression on B cells and primes B cells for Fas-mediated <z:hpo ids='HP_0011420'>death</z:hpo> signals </plain></SENT>
<SENT sid="2" pm="."><plain>In this work, we examine whether this CD4+ T-cell-dependent molecular pathway for Fas upregulation and B-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> reflects a peculiarity of the Ramos B-cell line or is applicable to other <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumors</z:e> as well </plain></SENT>
<SENT sid="3" pm="."><plain>In 5 of the 6 Epstein-Barr virus-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines examined, the cells constitutively express undetectable or low levels of Fas and are resistant to Fas-mediated signals induced by monoclonal anti-Fas antibody </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 6 of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line B cells upregulate Fas in response to CD40 ligation, and in 4 of the cases they become sensitive to Fas-mediated <z:hpo ids='HP_0011420'>death</z:hpo> signals </plain></SENT>
<SENT sid="5" pm="."><plain>In one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line, the cells are constitutively sensitive to Fas-mediated cytolysis and are unaffected by CD40 signals </plain></SENT>
<SENT sid="6" pm="."><plain>Next, we applied these immunologic manipulations to cells from a refractory clinical sample and observed that the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells could be induced to express Fas and undergo <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in our system </plain></SENT>
<SENT sid="7" pm="."><plain>These results establish CD4+ T cells and the Fas-Fas ligand system as important immune regulators of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> B cells and indicate that the susceptibility of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells to Fas-mediated <z:hpo ids='HP_0011420'>death</z:hpo> signals can be modulated by specific activation events at the cell surface </plain></SENT>
</text></document>